Peptide Schedule
Desmopressin (DDAVP)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Desmopressin (DDAVP) Dosage Calculator
Desmopressin (DDAVP) is a first-line synthetic vasopressin analog approved by the FDA for the management of central diabetes insipidus, primary nocturnal enuresis in patients aged 6 years and older, and as a hemostatic agent in mild hemophilia A and type 1 von Willebrand disease.
1mcg · Daily
Summary: Add 0mL BAC water to your 0.004mg vial. Draw to < 0.1 units on a U-100 syringe for a 1mcg dose. This vial will last 0 doses.
Cycle Planner
Desmopressin (DDAVP) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 2.5-3.5 hours (subcutaneous/IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Desmopressin (DDAVP) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mcg | Daily |
| Moderate | 2mcg | 2x Daily |
| Aggressive | 4mcg | 2x Daily |
Note: Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is a synthetic analog of the natural antidiuretic hormone vasopressin (ADH). It was first approved by the FDA in 1978 and remains a cornerstone treatment for central diabetes insipidus, primary nocturnal enuresis, and mild hemophilia A/von Willebrand disease type 1. Desmopressin is structurally modified from native vasopressin with deamination at position 1 and substitution of D-arginine at position 8, granting it dramatically enhanced antidiuretic potency (approximately 10-fold greater than vasopressin), a prolonged duration of action, and negligible vasopressor activity. It is available as injectable (IV/SC), intranasal spray, and oral tablet formulations. The injectable form is supplied as a 4 mcg/mL solution and does not require reconstitution. Fluid intake must be carefully managed during therapy to prevent hyponatremia and water intoxication, the most serious potential adverse effect.
About Desmopressin (DDAVP)
Desmopressin (DDAVP) is a first-line synthetic vasopressin analog approved by the FDA for the management of central diabetes insipidus, primary nocturnal enuresis in patients aged 6 years and older, and as a hemostatic agent in mild hemophilia A and type 1 von Willebrand disease. Originally developed in the 1970s, desmopressin represented a breakthrough in peptide engineering by selectively targeting vasopressin V2 receptors in the renal collecting ducts while minimizing activation of V1a receptors responsible for vasoconstriction. This selectivity allows clinicians to harness its potent antidiuretic effects without the cardiovascular side effects associated with native vasopressin. In the kidney, desmopressin binds to V2 receptors on the basolateral membrane of principal cells in the collecting duct, triggering a Gs-protein/adenylate cyclase/cAMP signaling cascade that promotes translocation of aquaporin-2 water channels to the apical membrane. This dramatically increases water reabsorption, concentrates the urine, and reduces urine output — effectively replacing the missing or insufficient endogenous ADH in patients with central diabetes insipidus. For hemostatic indications, desmopressin acts on endothelial V2 receptors to stimulate exocytosis of Weibel-Palade body contents, rapidly releasing stored von Willebrand factor (VWF) multimers and factor VIII into the circulation. This can raise factor VIII levels 3- to 5-fold within 30 to 60 minutes, providing sufficient hemostatic coverage for minor surgeries and bleeding episodes without the need for blood product transfusions. This nontransfusional approach has transformed the management of mild bleeding disorders. Desmopressin is available in multiple formulations: the injectable form (4 mcg/mL for IV or subcutaneous use), intranasal spray (Stimate at 1.5 mg/mL for hemostatic use, or standard 0.1 mg/mL nasal spray for diabetes insipidus), and oral tablets (0.1 mg and 0.2 mg). The injectable route offers near-complete bioavailability and is the preferred route in clinical and research settings for precise dosing.